<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195298</url>
  </required_header>
  <id_info>
    <org_study_id>ML22373</org_study_id>
    <nct_id>NCT01195298</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Eastern European Research Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>South Eastern European Research Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab&#xD;
      administered as first-line treatment of previously untreated elderly patients, older than 70&#xD;
      years, with metastatic or locally recurrent breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment progression</measure>
    <time_frame>average 5 years</time_frame>
    <description>followed until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate in patients with measurable disease at baseline</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (complete response, partial response and stable disease) in patients with measurable disease at baseline</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Bevacizumab</intervention_name>
    <description>Drugs will be administered in 3-week cycles as follows:&#xD;
Bevacizumab 15mg/kg via i.v. infusion on day 1&#xD;
Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.</description>
    <other_name>Bevacizumab (Avastin )</other_name>
    <other_name>Capecitabine (Xeloda)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent obtained prior to initiation of any study specific procedures&#xD;
             and treatment as confirmation of the patient's awareness and willingness to comply&#xD;
             with the Protocol code: ML22373 Protocol SEEROG: version 1.2. Date: October 15, 2009 3&#xD;
             study requirements;&#xD;
&#xD;
          -  Age ≥70 years;&#xD;
&#xD;
          -  Pathologically confirmed and documented metastatic breast cancer or locally recurrent&#xD;
             breast cancer not amenable to curative treatment. Complete radiology and tumor&#xD;
             measurement workup must be completed within 4 weeks prior to first study treatment;&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria;&#xD;
&#xD;
          -  HER2 negative disease;&#xD;
&#xD;
          -  No prior treatment for metastatic or locally recurrent disease;&#xD;
&#xD;
          -  Prior radiotherapy is allowed if delivered at least 2 weeks before enrolment in the&#xD;
             study and for the relief of metastatic bone pain, and provided that no more than 30%&#xD;
             of marrow bearing bone was irradiated and that target lesions were not included in the&#xD;
             radiotherapy field;&#xD;
&#xD;
          -  Not suitable for aggressive chemotherapy regimen in the opinion of the investigator;&#xD;
&#xD;
          -  Performance status ECOG 0 - 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior neoadjuvant or adjuvant treatment with anthracyclines completed less than 6&#xD;
             months prior to enrolment. The maximum cumulative dose received must not have exceeded&#xD;
             360 mg/m2 for doxorubicin or 720 mg/m2 for epirubicin. Prior anti-epidermal growth&#xD;
             factor therapy is allowed;&#xD;
&#xD;
          -  Concurrent hormonal therapy; however previous hormonal therapy is allowed for&#xD;
             adjuvant, locally recurrent, or metastatic breast cancer if completed within ≥1 months&#xD;
             prior to enrolment;&#xD;
&#xD;
          -  History or clinical evidence of brain metastases. If there is any clinical suspicion&#xD;
             of brain metastasis, a computerized tomography (CT) scan or magnetic resonance imaging&#xD;
             (MRI) of the brain must be conducted within 4 weeks prior to enrolment;&#xD;
&#xD;
          -  Other malignancy (including primary brain tumors) within the Protocol code: ML22373&#xD;
             Protocol SEEROG: version 1.2. Date: October 15, 2009 4 last 5 years, which could&#xD;
             affect the diagnosis or assessment of breast cancer, except for adequately treated&#xD;
             carcinoma in situ of the cervix, squamous carcinoma of the skin, or adequately&#xD;
             controlled limited basal cell skin cancer;&#xD;
&#xD;
          -  Life expectancy &lt; 12 weeks;&#xD;
&#xD;
          -  Any of the following abnormal values:&#xD;
&#xD;
               -  Inadequate bone marrow function: hemoglobin (Hb) &lt; 8.0 g/dL, absolute neutrophil&#xD;
                  count (ANC) &lt; 1.5 x 109/L, or platelet count &lt; 100 x 109/L;&#xD;
&#xD;
               -  Inadequate liver function: AST/SGOT or ALT/SGPT &gt; 2.5 x upper limit of normal&#xD;
                  (ULN) or &gt; 5 x ULN in patients with liver metastases), serum alkaline phosphatase&#xD;
                  &gt; 2.5 ULN or &gt; 5 x ULN in patients with liver metastases, or &gt; 10 x ULN in&#xD;
                  patients with bone metastases or total bilirubin &gt; 2 x ULN;&#xD;
&#xD;
               -  Moderate or severe renal impairment: creatinine clearance ≤50 mL/min (calculated&#xD;
                  according to the cockcroft and Gault formula; see Appendix 1), or serum&#xD;
                  creatinine &gt; 1.5 x ULN;&#xD;
&#xD;
          -  Chronic daily treatment with aspirin (&gt; 325 mg/day) or clopidogrel (&gt; 75 mg / day);&#xD;
&#xD;
          -  Chronic daily treatment with corticosteroids (dose of &gt; 10 mg/day methylprednisolone&#xD;
             equivalent) (excluding inhaled steroids);&#xD;
&#xD;
          -  Requirement for concurrent use of the antiviral agents sorivudine or brivudine;&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to enrolment, or anticipation of the need for major surgery during the course of&#xD;
             the study treatment;&#xD;
&#xD;
          -  Minor surgical procedures, within 24 hours prior to enrolment;&#xD;
&#xD;
          -  Current or recent (within the 30 days prior to starting study treatment) treatment&#xD;
             with another investigational drug or participation in another investigational study.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or&#xD;
             clinically significant (i.e. active) cardiovascular disease, including:&#xD;
&#xD;
          -  Cerebrovascular accident/stroke (≤ 6 months prior to enrolment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Vrdoljak, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Split, Center of oncology, Croatia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damir Vrbanec, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Zagreb, Croatia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarina Petrakova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masaryk Memorial Cancer Institue, Brno, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyorgy Bodoky, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FOVAROSI SZENT LASZLO KORHAZ-RENDELOINTEZET, ONKOLOGIAI OSZTALY, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamas Pinter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petz, Aladar Korhaz, Onkoradiologiai Osztaly, Gyor, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Todorović, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology clinic, Clinical Center of Montenegro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Wojtukiewicz, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology Medical University, Bialystok, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tadeusz Pienkowski, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Centre and Institute of Oncology Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela Grecea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Prof Dr. I Chiricuta&quot; Cluj Napoca Oncology Institute - Breast Cancer Center, Cluj Napoca, Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Split, Center of oncology</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Vrdoljak, PhD MD</last_name>
      <phone>00385-21-556-129</phone>
      <email>eduard.vrdoljak@st.htnet.hr</email>
    </contact>
    <investigator>
      <last_name>Eduard Vrdoljak, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>September 3, 2010</last_update_submitted>
  <last_update_submitted_qc>September 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. sc. Eduard Vrdoljak</name_title>
    <organization>Clinical Hospitl Split, Center of oncology</organization>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>elderly patients</keyword>
  <keyword>chemoimmunotherapy</keyword>
  <keyword>Triple negative metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

